World first Australian and New Zealand trial of cannabidiol transdermal gel for the most common hard-to-treat epilepsy type in adults

Professor Terry O'Brien has led a trial using transdermal CBD gel
in adults with focal epilepsy. After 6 months of treatment, over half
the patients experienced a 50%+ reduction in seizures. JAMA study

Medicinal cannabis-based treatments are emerging as promising complementary approaches to improving seizure control in patients with difficult to treat epilepsy. In 2018 the US Food and Drug Administration (FDA) approved the use of a prescription cannabidiol medicine for the treatment of two rare epilepsy diseases that cause treatment resistant seizures, Lennox-Gastaut Syndrome and Dravet syndrome, that predominantly affect children.